Personalised therapy and biomarkers

We are developing tools for selecting personalised treatment plans and predicting outcomes for patients.

This builds on our pioneering work in chronic lymphocytic leukaemia, where we demonstrated strong links between genetic factors and outcomes after treatment.

Our ‘biobank’ of tissue samples, given by Southampton cancer patients through the work of the Experimental Cancer Medicine Centre, is critical to this work understanding the different biological markers (‘biomarkers’) associated with cancer progression.

It also provides vital information to understand patients' responses to immune-based treatments, and to repeatedly refine these treatments.